RTTNews | Aug 24, 2021 08:18AM EDT

08:18 Tuesday, August 24, 2021 (RTTNews.com) - AbbVie (ABBV) said the European Commission has approved RINVOQ for the treatment of moderate to severe atopic dermatitis in adults and adolescents. The company noted that this marks the fourth EC-approved indication for RINVOQ.

RINVOQ is now approved in all member states of the European Union, as well as Iceland, Liechtenstein, Norway and Northern Ireland. It is currently under review by the FDA.

RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases. Phase 3 trials in rheumatoid arthritis, atopic dermatitis, psoriatic arthritis, axial spondyloarthritis, Crohn's disease, ulcerative colitis, giant cell arteritis and Takayasu arteritis are ongoing.

Read the original article on RTTNews ( https://www.rttnews.com/3220715/abbvie-announces-ec-approval-of-rinvoq-in-treatment-of-moderate-to-severe-atopic-dermatitis.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved